Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.48
SYK's Cash to Debt is ranked lower than
75% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.24 vs. SYK: 0.48 )
Ranked among companies with meaningful Cash to Debt only.
SYK' s Cash to Debt Range Over the Past 10 Years
Min: 0.04  Med: 1.86 Max: 164.16
Current: 0.48
0.04
164.16
Equity to Asset 0.44
SYK's Equity to Asset is ranked lower than
77% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. SYK: 0.44 )
Ranked among companies with meaningful Equity to Asset only.
SYK' s Equity to Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.63 Max: 0.78
Current: 0.44
0.22
0.78
Interest Coverage N/A
SYK's Interest Coverage is ranked higher than
72% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 69.16 vs. SYK: N/A )
Ranked among companies with meaningful Interest Coverage only.
SYK' s Interest Coverage Range Over the Past 10 Years
Min: 24.66  Med: N/A Max: No Debt
Current: N/A
F-Score: 6
Z-Score: 3.87
M-Score: -2.04
WACC vs ROIC
5.72%
18.82%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 19.53
SYK's Operating margin (%) is ranked higher than
89% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. SYK: 19.53 )
Ranked among companies with meaningful Operating margin (%) only.
SYK' s Operating margin (%) Range Over the Past 10 Years
Min: 12.88  Med: 20.48 Max: 23.92
Current: 19.53
12.88
23.92
Net-margin (%) 15.33
SYK's Net-margin (%) is ranked higher than
86% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 1.43 vs. SYK: 15.33 )
Ranked among companies with meaningful Net-margin (%) only.
SYK' s Net-margin (%) Range Over the Past 10 Years
Min: 5.32  Med: 15.65 Max: 17.39
Current: 15.33
5.32
17.39
ROE (%) 18.49
SYK's ROE (%) is ranked higher than
87% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. SYK: 18.49 )
Ranked among companies with meaningful ROE (%) only.
SYK' s ROE (%) Range Over the Past 10 Years
Min: 5.84  Med: 18.28 Max: 21.28
Current: 18.49
5.84
21.28
ROA (%) 9.00
SYK's ROA (%) is ranked higher than
82% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: -0.39 vs. SYK: 9.00 )
Ranked among companies with meaningful ROA (%) only.
SYK' s ROA (%) Range Over the Past 10 Years
Min: 3.12  Med: 12.21 Max: 15.38
Current: 9
3.12
15.38
ROC (Joel Greenblatt) (%) 76.37
SYK's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 4.23 vs. SYK: 76.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SYK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 43.65  Med: 67.6 Max: 108.58
Current: 76.37
43.65
108.58
Revenue Growth (3Y)(%) 4.90
SYK's Revenue Growth (3Y)(%) is ranked higher than
55% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. SYK: 4.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SYK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.9  Med: 11.4 Max: 32.9
Current: 4.9
4.9
32.9
EBITDA Growth (3Y)(%) 4.00
SYK's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 192 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. SYK: 4.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SYK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.6  Med: 13.7 Max: 59.8
Current: 4
-9.6
59.8
EPS Growth (3Y)(%) 3.70
SYK's EPS Growth (3Y)(%) is ranked higher than
53% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. SYK: 3.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SYK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -42.6  Med: 16.6 Max: 153
Current: 3.7
-42.6
153
» SYK's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-22)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

SYK Guru Trades in Q3 2015

Steven Cohen 255,600 sh (New)
John Hussman 30,000 sh (New)
Louis Moore Bacon 120,000 sh (+140.00%)
Paul Tudor Jones 7,500 sh (+77.98%)
PRIMECAP Management 295,500 sh (unchged)
Vanguard Health Care Fund 1,433,500 sh (unchged)
Dodge & Cox 3,360 sh (unchged)
Jim Simons Sold Out
Joel Greenblatt Sold Out
Eric Mindich Sold Out
Ray Dalio Sold Out
Diamond Hill Capital 923,529 sh (-6.31%)
Yacktman Fund 2,000,000 sh (-16.67%)
Jeremy Grantham 1,690,876 sh (-20.54%)
Robert Olstein 49,000 sh (-35.53%)
Donald Yacktman 3,143,750 sh (-35.63%)
Yacktman Focused Fund 400,000 sh (-75.00%)
» More
Q4 2015

SYK Guru Trades in Q4 2015

Ray Dalio 12,164 sh (New)
Jim Simons 26,100 sh (New)
Pioneer Investments 26,932 sh (New)
Paul Tudor Jones 207,500 sh (+2666.67%)
Vanguard Health Care Fund 2,498,900 sh (+74.32%)
Robert Olstein 52,000 sh (+6.12%)
Diamond Hill Capital 936,985 sh (+1.46%)
PRIMECAP Management 295,500 sh (unchged)
Yacktman Focused Fund Sold Out
Louis Moore Bacon Sold Out
John Hussman Sold Out
Dodge & Cox Sold Out
Jeremy Grantham 1,467,369 sh (-13.22%)
Yacktman Fund 1,700,000 sh (-15.00%)
Donald Yacktman 2,061,165 sh (-34.44%)
Steven Cohen 18,800 sh (-92.64%)
» More
Q1 2016

SYK Guru Trades in Q1 2016

Murray Stahl 2,000 sh (New)
George Soros 20,300 sh (New)
Joel Greenblatt 85,828 sh (New)
Pioneer Investments 37,559 sh (+39.46%)
Vanguard Health Care Fund 2,498,900 sh (unchged)
PRIMECAP Management 295,500 sh (unchged)
Steven Cohen Sold Out
Jim Simons Sold Out
Ray Dalio Sold Out
Diamond Hill Capital 917,488 sh (-2.08%)
Donald Yacktman 1,948,574 sh (-5.46%)
Yacktman Fund 1,600,000 sh (-5.88%)
Jeremy Grantham 1,287,095 sh (-12.29%)
Robert Olstein 45,000 sh (-13.46%)
Paul Tudor Jones 4,200 sh (-97.98%)
» More
Q2 2016

SYK Guru Trades in Q2 2016

Pioneer Investments 43,865 sh (+16.79%)
Jeremy Grantham 1,321,268 sh (+2.66%)
Vanguard Health Care Fund 2,498,900 sh (unchged)
Murray Stahl 2,000 sh (unchged)
PRIMECAP Management 295,500 sh (unchged)
George Soros Sold Out
Diamond Hill Capital 883,282 sh (-3.73%)
Paul Tudor Jones 3,700 sh (-11.90%)
Robert Olstein 38,000 sh (-15.56%)
Joel Greenblatt 63,965 sh (-25.47%)
Donald Yacktman 1,402,704 sh (-28.01%)
Yacktman Fund 1,100,000 sh (-31.25%)
» More
» Details

Insider Trades

Latest Guru Trades with SYK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NYSE:BSX, NAS:ISRG, NYSE:ZBH, NYSE:EW, NYSE:STJ, NYSE:ABT, OTCPK:SNNUF, OTCPK:SONVY, NYSE:VAR, NYSE:TFX, NAS:ALGN, OTCPK:SDMHF, OTCPK:CHEOY, OTCPK:WILLF, NAS:ABMD, OTCPK:FSPKF, NAS:IART, OTCPK:EKTAF, OTCPK:GGNDF, NAS:NUVA » details
Traded in other countries:SYK.Germany, SYK.Switzerland, 0R2S.UK,
Stryker Corporation is a medical technology company. The Company offers medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products.

Stryker Corp was incorporated in Michigan in 1946. It is a medical technology company. The Company offers medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products. Its business segments are Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics products consist of implants used in hip and knee joint replacements and trauma and extremities surgeries. The Company supports surgeons with the technology and services needed as the company develops new surgical techniques. The MedSurg products include surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical); and reprocessed and remanufactured medical devices (Sustainability) as well as other medical device products used in a variety of medical specialties. The Neurotechnology and Spine products include both neurosurgical and neurovascular devices. Its neurotechnology offering includes products used for minimally invasive endovascular techniques; a comprehensive line of products for traditional brain and open skull base surgical procedures; orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also develops, manufacture and market spinal implant products including cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. The Company's competitors include Zimmer Biomet Holdings, Inc. (Zimmer), DePuy Synthes (companies of Johnson & Johnson) and Smith & Nephew plc (Smith & Nephew). The Company's businesses are subject to varying degrees of governmental regulation in the countries in which the company operates and the general trend is toward increasingly stringent regulation.

Top Ranked Articles about Stryker Corp

Answers to the Hardest Question: When Do I Sell a Stock? There are 2 primary reasons it makes sense to sell a stock
The most common complaint I have heard from investors over my 40-plus years in the financial services industry is as follows: "Everyone wants to tell me what to buy and when, but no one ever tells me when to sell." Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 26.72
SYK's P/E(ttm) is ranked higher than
52% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 27.51 vs. SYK: 26.72 )
Ranked among companies with meaningful P/E(ttm) only.
SYK' s P/E(ttm) Range Over the Past 10 Years
Min: 11.3  Med: 24.99 Max: 71.37
Current: 26.72
11.3
71.37
Forward P/E 19.57
SYK's Forward P/E is ranked higher than
75% of the 51 Companies
in the Global Medical Devices industry.

( Industry Median: 24.51 vs. SYK: 19.57 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 26.72
SYK's PE(NRI) is ranked higher than
51% of the 166 Companies
in the Global Medical Devices industry.

( Industry Median: 27.51 vs. SYK: 26.72 )
Ranked among companies with meaningful PE(NRI) only.
SYK' s PE(NRI) Range Over the Past 10 Years
Min: 11.3  Med: 25.33 Max: 71.37
Current: 26.72
11.3
71.37
Price/Owner Earnings (ttm) 219.16
SYK's Price/Owner Earnings (ttm) is ranked lower than
91% of the 108 Companies
in the Global Medical Devices industry.

( Industry Median: 31.29 vs. SYK: 219.16 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
SYK' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 12.61  Med: 26.03 Max: 340.76
Current: 219.16
12.61
340.76
P/B 4.68
SYK's P/B is ranked lower than
65% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.93 vs. SYK: 4.68 )
Ranked among companies with meaningful P/B only.
SYK' s P/B Range Over the Past 10 Years
Min: 2.19  Med: 3.43 Max: 7.08
Current: 4.68
2.19
7.08
P/S 4.12
SYK's P/S is ranked lower than
62% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 3.21 vs. SYK: 4.12 )
Ranked among companies with meaningful P/S only.
SYK' s P/S Range Over the Past 10 Years
Min: 1.94  Med: 3.35 Max: 5.29
Current: 4.12
1.94
5.29
PFCF 95.78
SYK's PFCF is ranked lower than
94% of the 97 Companies
in the Global Medical Devices industry.

( Industry Median: 27.16 vs. SYK: 95.78 )
Ranked among companies with meaningful PFCF only.
SYK' s PFCF Range Over the Past 10 Years
Min: 11.77  Med: 19.91 Max: 111.1
Current: 95.78
11.77
111.1
POCF 51.52
SYK's POCF is ranked lower than
90% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. SYK: 51.52 )
Ranked among companies with meaningful POCF only.
SYK' s POCF Range Over the Past 10 Years
Min: 10.32  Med: 17.09 Max: 58.83
Current: 51.52
10.32
58.83
EV-to-EBIT 22.71
SYK's EV-to-EBIT is ranked lower than
52% of the 161 Companies
in the Global Medical Devices industry.

( Industry Median: 22.46 vs. SYK: 22.71 )
Ranked among companies with meaningful EV-to-EBIT only.
SYK' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 14.95 Max: 35.3
Current: 22.71
6.8
35.3
EV-to-EBITDA 18.54
SYK's EV-to-EBITDA is ranked lower than
51% of the 170 Companies
in the Global Medical Devices industry.

( Industry Median: 18.25 vs. SYK: 18.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
SYK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.5  Med: 12.3 Max: 25.6
Current: 18.54
5.5
25.6
Shiller P/E 36.56
SYK's Shiller P/E is ranked higher than
59% of the 46 Companies
in the Global Medical Devices industry.

( Industry Median: 44.17 vs. SYK: 36.56 )
Ranked among companies with meaningful Shiller P/E only.
SYK' s Shiller P/E Range Over the Past 10 Years
Min: 20.36  Med: 30.13 Max: 71.26
Current: 36.56
20.36
71.26
Current Ratio 2.17
SYK's Current Ratio is ranked lower than
57% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. SYK: 2.17 )
Ranked among companies with meaningful Current Ratio only.
SYK' s Current Ratio Range Over the Past 10 Years
Min: 1.61  Med: 2.58 Max: 5.37
Current: 2.17
1.61
5.37
Quick Ratio 1.62
SYK's Quick Ratio is ranked lower than
57% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. SYK: 1.62 )
Ranked among companies with meaningful Quick Ratio only.
SYK' s Quick Ratio Range Over the Past 10 Years
Min: 0.98  Med: 2.1 Max: 4.63
Current: 1.62
0.98
4.63
Days Inventory 181.56
SYK's Days Inventory is ranked lower than
69% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 133.25 vs. SYK: 181.56 )
Ranked among companies with meaningful Days Inventory only.
SYK' s Days Inventory Range Over the Past 10 Years
Min: 140.11  Med: 159.05 Max: 181.56
Current: 181.56
140.11
181.56
Days Sales Outstanding 61.29
SYK's Days Sales Outstanding is ranked higher than
62% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 68.90 vs. SYK: 61.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
SYK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 59.31  Med: 61.46 Max: 62.7
Current: 61.29
59.31
62.7
Days Payable 44.45
SYK's Days Payable is ranked lower than
64% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 58.34 vs. SYK: 44.45 )
Ranked among companies with meaningful Days Payable only.
SYK' s Days Payable Range Over the Past 10 Years
Min: 33.46  Med: 44.78 Max: 55.97
Current: 44.45
33.46
55.97

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.32
SYK's Dividend Yield is ranked lower than
60% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 1.66 vs. SYK: 1.32 )
Ranked among companies with meaningful Dividend Yield only.
SYK' s Dividend Yield Range Over the Past 10 Years
Min: 0.16  Med: 1.18 Max: 1.66
Current: 1.32
0.16
1.66
Dividend Payout 0.35
SYK's Dividend Payout is ranked higher than
67% of the 118 Companies
in the Global Medical Devices industry.

( Industry Median: 0.38 vs. SYK: 0.35 )
Ranked among companies with meaningful Dividend Payout only.
SYK' s Dividend Payout Range Over the Past 10 Years
Min: 0.18  Med: 0.28 Max: 1.91
Current: 0.35
0.18
1.91
Dividend Growth (3y) 16.20
SYK's Dividend Growth (3y) is ranked higher than
67% of the 76 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. SYK: 16.20 )
Ranked among companies with meaningful Dividend Growth (3y) only.
SYK' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 21.6 Max: 81.9
Current: 16.2
0
81.9
Forward Dividend Yield 1.35
SYK's Forward Dividend Yield is ranked lower than
65% of the 160 Companies
in the Global Medical Devices industry.

( Industry Median: 1.81 vs. SYK: 1.35 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.02
SYK's Yield on cost (5-Year) is ranked higher than
70% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. SYK: 3.02 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SYK' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.37  Med: 2.7 Max: 3.8
Current: 3.02
0.37
3.8
3-Year Average Share Buyback Ratio 0.60
SYK's 3-Year Average Share Buyback Ratio is ranked higher than
88% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. SYK: 0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SYK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: -0.1 Max: 1.9
Current: 0.6
-0.8
1.9

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.08
SYK's Price/Projected FCF is ranked higher than
51% of the 128 Companies
in the Global Medical Devices industry.

( Industry Median: 2.12 vs. SYK: 2.08 )
Ranked among companies with meaningful Price/Projected FCF only.
SYK' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.92  Med: 1.79 Max: 99.06
Current: 2.08
0.92
99.06
Price/Median PS Value 1.23
SYK's Price/Median PS Value is ranked lower than
61% of the 260 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. SYK: 1.23 )
Ranked among companies with meaningful Price/Median PS Value only.
SYK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.63  Med: 1.11 Max: 1.71
Current: 1.23
0.63
1.71
Earnings Yield (Greenblatt) (%) 4.43
SYK's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. SYK: 4.43 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SYK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.8  Med: 6.7 Max: 14.6
Current: 4.43
2.8
14.6
Forward Rate of Return (Yacktman) (%) 3.91
SYK's Forward Rate of Return (Yacktman) (%) is ranked lower than
59% of the 117 Companies
in the Global Medical Devices industry.

( Industry Median: 7.47 vs. SYK: 3.91 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SYK' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -3  Med: 13.6 Max: 28.1
Current: 3.91
-3
28.1

More Statistics

Revenue (TTM) (Mil) $10,470
EPS (TTM) $ 4.24
Beta0.63
Short Percentage of Float1.59%
52-Week Range $86.68 - 123.55
Shares Outstanding (Mil)374.30

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 11,235 12,160 12,890
EPS ($) 5.66 6.26 6.81
EPS w/o NRI ($) 5.66 6.26 6.81
EPS Growth Rate
(3Y to 5Y Estimate)
8.01%
Dividends Per Share ($) 1.46 1.56 1.89
» More Articles for SYK

Headlines

Articles On GuruFocus.com
Johnson & Johnson Reports 4% Sales Growth for the Second Quarter Jul 22 2016 
Becton Dickinson: 19% EPS Growth With Good Dividends Jun 26 2016 
Answers to the Hardest Question: When Do I Sell a Stock? Jun 23 2016 
Weekly Insider Sells: Medivation, JPMorgan Chase, Stryker, Sabre Jan 26 2016 
Stryker: An Expensive Growth Play Dec 26 2015 
Louis Moore Bacon's Largest 3rd Quarter Trades Dec 23 2015 
Eric Mindich Sells Stakes in Catamaran and Alphabet in 3rd Quarter Dec 02 2015 
Weekly Insider Sells Highlights: Nike, Intuitive Surgical, Travelers Companies, Stryker Oct 26 2015 
Donald Yacktman Comments on Stryker and Anthem Aug 06 2015 
Yacktman Focused Fund 2nd Quarter 2015 Commentary Aug 05 2015 

More From Other Websites
Medovex Corporation Adds 35 Year Orthopedic Industry Veteran Ron Lawson to Board of Directors Aug 25 2016
Discussing Stryker’s Latest Valuation Aug 25 2016
A Look at Stryker’s Updated Guidance for 2016 Aug 24 2016
Analyzing SYK’s Capital Deployment Strategy for Investor Value Aug 24 2016
Stryker Continues to Exhibit a Strong Inorganic Growth Strategy Aug 24 2016
How Stryker Plans to Leverage the Under-Tapped Europe Opportunity Aug 24 2016
How MAKO Robots Could Contribute to SYK’s Orthopedics Growth Aug 24 2016
New Product Launches Drive Stryker’s Growth and Profitability Aug 24 2016
A Look at Stryker’s Consistently Growing Revenue Profile Aug 24 2016
Analysts’ Latest Recommendations for Stryker Aug 24 2016
STRYKER CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Aug 23 2016
ETF’s with exposure to Stryker Corp. : August 15, 2016 Aug 15 2016
Why Medical Devices ETF Is Among The Winners Of 2016 Aug 05 2016
ETF’s with exposure to Stryker Corp. : August 4, 2016 Aug 04 2016
Stryker Corp. :SYK-US: Earnings Analysis: Q2, 2016 By the Numbers : August 2, 2016 Aug 02 2016
Cramer: A speculative play on pot Jul 28 2016
STRYKER CORP Financials Jul 28 2016
Weak China sales drag down Smith & Nephew profits Jul 28 2016
AngioDynamics Issues Statement Regarding Stryker recall of Angiographic Catheters Jul 27 2016
Stryker declares a $0.38 per share quarterly dividend Jul 27 2016
Stryker declares a $0.38 per share quarterly dividend Jul 27 2016
AngioDynamics Issues Statement Regarding Stryker recall of Angiographic Catheters Jul 26 2016
Stryker Corp. breached its 50 day moving average in a Bearish Manner : SYK-US : July 26, 2016 Jul 26 2016
Fresh Research Reports For Intel (INTC), AT&T (T) & Others Jul 25 2016
How Did JNJ’s Medical Devices Segment Perform in 2Q16? Jul 25 2016
Johnson & Johnson Reports 4% Sales Growth for the Second Quarter Jul 22 2016
STRYKER CORP Files SEC form 10-Q, Quarterly Report Jul 22 2016
Stryker beats Street 2Q forecasts Jul 21 2016
Accenture Selected to Help Stryker Improve Operating Efficiencies Jun 29 2016
Stryker to host conference call on July 21, 2016 Jun 16 2016
Stryker, Halo to get second chance at enhanced patent damages Jun 13 2016
Stryker to participate in Goldman Sachs 37th Annual Global Healthcare Conference May 31 2016
Stryker to participate in UBS 2016 Global Healthcare Conference May 17 2016
Stryker to participate in Bank of America Merrill Lynch 2016 Health Care Conference May 02 2016
Stryker acquires Stanmore Implants Worldwide Limited Apr 29 2016
Stryker declares a $0.38 per share quarterly dividend Apr 27 2016
Stryker announces completion of the acquisition of vertebral compression fracture portfolio from BD Apr 21 2016
BD Divests Vertebral Augmentation Solutions Business to Stryker Apr 21 2016
Stryker reports first quarter 2016 results Apr 20 2016
Stryker tops Street 1Q forecasts Apr 20 2016
Stryker completes acquisition of Physio-Control International, Inc. Apr 05 2016
Stryker completes acquisition of Sage Products, LLC Apr 01 2016
Stryker completes the acquisition of Synergetics USA, Inc.'s Neuro Portfolio Apr 01 2016
Stryker announces Annual Meeting of Shareholders Mar 23 2016
EOS imaging and Stryker announce a Co-promotion Agreement for the UK market Mar 02 2016
U.S. top court mulls boosted patent damages in Stryker, Halo cases Feb 23 2016
Stryker buying Physio-Control for $1.28 billion Feb 16 2016
Stryker to buy medical supplier Sage Products Feb 01 2016
BUZZ-Smith & Nephew drops as Stryker buys Sage Products Feb 01 2016
Stryker Announces Definitive Agreement to Acquire Sage Products, LLC from Madison Dearborn Partners... Feb 01 2016
Stryker Reports 2015 Results and 2016 Outlook Jan 26 2016
Stryker beats Street 4Q forecasts Jan 26 2016
China slowdown leads to revenue miss for Smith & Nephew Oct 29 2015
Stryker tops 3Q profit forecasts Oct 22 2015
Stryker beats Street 2Q forecasts Jul 23 2015
Stryker beats 1Q profit forecasts Apr 21 2015
Stryker's $2 bln buyback plan deflates Smith & Nephew bid hopes Mar 03 2015
BUZZ-Smith & Nephew: top FTSE loser as Stryker share buyback dents M&A hopes Mar 03 2015
Stryker CEO says he remains focused on acquisitions Jan 27 2015
Stryker CEO says he remains focused on acquisitions Jan 27 2015
Stryker misses 4Q profit forecasts Jan 27 2015
BUZZ-U.S. STOCKS ON THE MOVE- Automobile stocks, Kite Pharma, Zimmer Jan 05 2015
Stryker planning takeover offer for Smith & Nephew - Bloomberg Dec 24 2014
US STOCKS-Futures flat after 5-day rally; jobless claims data on tap Dec 24 2014
Smith & Nephew surges as rumours resurface about Stryker takeover bid Dec 24 2014
Stryker planning takeover offer for Smith & Nephew - Bloomberg Dec 24 2014
Stryker planning takeover offer for Smith & Nephew - Bloomberg Dec 23 2014
Stryker will pay about $80M to end investigation Dec 08 2014
Stryker weighing bid for Smith & Nephew - Bloomberg Nov 24 2014
Stryker weighing bid for Smith & Nephew - Bloomberg Nov 24 2014
Stryker to pay $1.43B to settle hip implant cases Nov 03 2014
Stryker tops Street 3Q forecasts Oct 16 2014
Stryker buys joint device maker for up to $375M Jun 30 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)